MicroDose Therapeutx has announced that it has achieved a milestone that “signals the successful incorporation of MicroDose’s DPI technology into a Novartis platform pulmonary device” and triggers a milestone payment from Novartis.
The two companies entered into a development and licensing agreement for five products in June 2006. According to a press release at the time of the agreement, Novartis could pay MicroDose up to $125 million in milestone payments for development of the first product covered under the deal.
MicroDose also has its own pipeline and recently announced a licensing agreement with Gilead for its MDT-637 dry powder formulation for the treatment of respiratory syncytial virus (RSV).
Read the MicroDose press release.
